Laboratory of Biochemistry, Division of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
Cancer Biology Research Laboratory, Institute Pasteur Korea, 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea; Laboratory of Biochemistry, Division of Life Sciences, Korea University, Seoul 02841, Republic of Korea.
Life Sci. 2017 Sep 1;184:25-29. doi: 10.1016/j.lfs.2017.07.008. Epub 2017 Jul 8.
Cancer stem cells (CSCs) have emerged as an underlying cause of cancer relapse and resistance to treatment. Initially, biomarkers were used to identify and isolate distinct cell populations. Several CSC markers have been identified from many types of tumors, and these markers are also being used for isolation and enrichment of CSCs. Cluster of differentiation CD133 is a well-characterized CSC marker, and it is involved in tumor cell proliferation, metastasis, tumorigenesis, and recurrence, as well as chemo- and radio-resistance. However, the mechanisms involved in CD133-mediated induction of CSC properties have not yet been elucidated. Here, we introduce and summarize the functions of CD133 in CSCs and suggest new mechanisms that may be of note in our approach to developing novel cancer therapies.
癌症干细胞（CSCs）已成为癌症复发和治疗耐药的根本原因。最初，使用生物标志物来识别和分离不同的细胞群体。已经从多种类型的肿瘤中鉴定出多个 CSC 标志物，并且这些标志物也被用于 CSC 的分离和富集。分化簇 CD133 是一种特征明确的 CSC 标志物，它参与肿瘤细胞的增殖、转移、肿瘤发生和复发，以及化疗和放疗耐药。然而，CD133 介导的 CSC 特性诱导的机制尚未阐明。在这里，我们介绍并总结了 CD133 在 CSCs 中的功能，并提出了一些新的机制，这些机制可能在我们开发新型癌症治疗方法中值得注意。
